BioMarin Pharmaceutical Inc.
BMRN
$53.82
-$0.49-0.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.09B | 3.06B | 2.95B | 2.85B | 2.75B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.09B | 3.06B | 2.95B | 2.85B | 2.75B |
| Cost of Revenue | 897.91M | 946.28M | 949.13M | 969.01M | 970.80M |
| Gross Profit | 2.20B | 2.12B | 2.00B | 1.88B | 1.78B |
| SG&A Expenses | 963.58M | 948.64M | 979.40M | 999.19M | 1.00B |
| Depreciation & Amortization | 24.19M | 24.35M | 33.81M | 43.26M | 48.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.47B | 2.28B | 2.32B | 2.37B | 2.41B |
| Operating Income | 625.33M | 785.92M | 629.48M | 484.05M | 340.09M |
| Income Before Tax | 679.27M | 840.04M | 674.31M | 541.76M | 391.45M |
| Income Tax Expenses | 158.86M | 182.80M | 150.42M | 114.90M | 69.16M |
| Earnings from Continuing Operations | 520.42 | 657.24 | 523.88 | 426.86 | 322.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 520.42M | 657.24M | 523.88M | 426.86M | 322.29M |
| EBIT | 625.33M | 785.92M | 629.48M | 484.05M | 340.09M |
| EBITDA | 708.06M | 869.16M | 720.63M | 580.48M | 439.77M |
| EPS Basic | 2.72 | 3.44 | 2.75 | 2.25 | 1.70 |
| Normalized Basic EPS | 2.25 | 2.78 | 2.24 | 1.78 | 1.26 |
| EPS Diluted | 2.67 | 3.38 | 2.70 | 2.20 | 1.64 |
| Normalized Diluted EPS | 2.19 | 2.70 | 2.17 | 1.71 | 1.20 |
| Average Basic Shares Outstanding | 765.59M | 763.99M | 762.20M | 760.10M | 757.89M |
| Average Diluted Shares Outstanding | 782.18M | 787.29M | 790.71M | 793.50M | 788.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |